Todd Wenning of Ensemble Capital Management presented his in-depth investment thesis on Masimo (US: MASI) at Wide-Moat Investing Summit 2020.

Thesis summary:

Masimo is a medical technology company best known for its highly accurate pulse oximetry sensors used in critical care settings. Masimo’s mission is to improve patient outcomes while reducing system-wide costs, which is a rare strategy in the healthcare industry.

Most medical device companies are healthcare companies that use technology and are thus motivated to maintain the status quo of adding cost to the system. Masimo inverts this and is a technology company that focuses on healthcare. As such, Masimo starts with first principles when solving problems and creates solutions that are win-win-win for hospitals, medical professionals, and patients.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Todd Wenning is a senior investment analyst at Ensemble Capital. Before joining Ensemble, Todd was an analyst at Johnson Investment Counsel, where he worked on the firm’s SMID cap strategy. Prior to that, Todd was a sell-side analyst at Morningstar, where he led Morningstar’s equity stewardship methodology and covered companies in the basic materials, industrials, and consumer sectors. Earlier in his career, Todd worked for The Motley Fool, SunTrust Asset Management, and Vanguard. He holds a BA in History from Saint Joseph’s University in Philadelphia and the Chartered Financial Analyst designation.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.